FTD ALS Workshop - Schedule - Plenary Sessions / Topics

Sunday June 21, 2009

Included In Registration for:

Package A  |  Package B

1700 hrs Opening reception (wine & cheese)

1800 hrs Opening dinner

Session 1: Opening Session

Speaker Topic
Ralph Garruto, PhD Gene environment interactions – lessons from high incidence foci: A lecture in honor of D. Carleton Gajdusek
Thomas Bak, PhD Learning from history – ALS, FTD and behaviour
Top of Page

Monday June 22, 2009

Included In Registration for:

Package A  |  Package B

Session 2a: Phenotypic heterogeneity of ALS and the FTDs

Speaker Topic
Jeffery Rosenfeld, MD, PhD Phenotypic heterogeneity in ALS
John Ravits, MD Linkage between disease onset and progression
Daniel Perl, MD Late onset dementia amongst Chamorros
Shigeki Kuzuhara, MD ALS/PD complex in Kii Peninsula - advances

Session 2b: Exploring the spectrum of FTD phenomenology

Speaker Topic
Christopher Kipps, MD Theory of mind
Murray Grossman, MD Phenotypic heterogeneity in the FTDs
Sharon Abrahams, PhD Social cognition in ALS

Session 3: Neuroimaging advances

Speaker Topic
Sandra Black, MD Using neuroimaging to understand brain-behaviour relationships
Norbert Schuff, PhD Advances in MR imaging in ALS
Albert Ludolph, MD Multimodality approach to neuroimaging in ALS
Tiffany Chow, MD When is frontotemporal atrophy normal?
Sanjay Kalra, MD Using MR to measure success

Session 4: Poster session

Top of Page

Tuesday June 23, 2009

Included In Registration for:

Package A  |  Package B

Session 5: Preclinical detection

Speaker Topic
Howard Feldman, MD Preclinical detection of AD – lessons learned
Douglas Munoz, PhD The basis of saccadic and anti-saccadic impairments
John Katz, MD Saccadic pursuit in ALS

Session 6: Language in ALS & FTD

Speaker Topic
Argye Hillis, MD, MA Language in ALS/FTLD
Mitsuru Kawamura, MD Writing errors and anosagnosia in ALS
Vincenzo Silani, MD Dysgraphia in PLS
Florence Pasquier, MD Treatment in FTD
Laura Goldstein, PhD Implications of cognitive/behaviour changes

Session 7: Screening studies for frontotemporal syndromes in ALS; Treatment of FTD

Speaker Topic
Morris Freedman, MD Case presentation
Laura Goldstein, PhD An approach to the screening exam
Susan Woolley, PhD An approach to the screening exam
Claire Flaherty-Craig, PhD An approach to the screening exam
Laura Goldstein, PhD Implications of cognitive/behaviour changes
Florence Pasquier, MD Treatment in FTD
All Round table discussion

Tuesday Evening: Dinner and theatre at Stratford (limited seating – book early)

Top of Page

Wednesday June 24, 2009

Included In Registration for:

Package A  |  Package B  |  Package C

Session 8: Genetics

Speaker Topic
Ammar Al-Chalabi, PhD, FRCPC Controversies in genetics of ALS
Rosa Rademakers, Phd Overview of the genetics of the FTLDs
Paul Schulz, MD Cognitive impairment in familial ALS
Chris Shaw, MD FUS mutations
All Round table discussion

Session 9: Biomarkers

Speaker Topic
Martin Turner, MRCP, PhD Biomarkers in ALS – an overview
Bob Bowser, PhD CSF biomarkers – pitfalls and promises
James R Connor, PhD CSF biomarkers – use of a panel
Konen Obayashi, MD, PhD Salivary gland chromogranin
All Round table discussion

Session 10: TDP-43

Speaker Topic
Emanuele Buratti, PhD TDP-43: so what is all the excitement about?
Paul Ince, FRCPath, PhD The Neuropathology of MNDs – recent advances
John Trojanowski, MD, PhD The Neuropathology of the FTDs – recent advances
Janice Robertson, PhD TDP-43 aggregate composition
Chris Shaw, MD Genetics of TDP-43
Michael Strong, MD TDP-43 as an RNA stability determinant
Takahiko Tokuda, MD, PhD CSF TDP-43 as a biomarker
All Round table discussion
Top of Page

Thursday June 25, 2009

Included In Registration for:

Package B  |  Package C

Session 11a: Experimental modeling of TDP-43 pathology

Speaker Topic
Kathryn Volkening, PhD Pluripotential role of TDP-43 as a dual RNA/protein interactor
Ronald Klein, PhD Rat model of TDP-43 expression
Brian Kraemer, PhD C. Elegans model of TDP-43 expression
Philip Van Damme, MD Zebra fish model of TDP-43 and progranulin
David Morton, PhD Drosophila model of TDP-43 over-expression
Don Cleveland, PhD Murine models of TDP-43 expression
Hugh Bennett, PhD Models of progranulin function and mutations
All Round table discussion

Session 11b: Functional biochemistry of TDP-43

Speaker Topic
Leonard Petrucelli, PhD TDP-43 & progranulin: is there a relationship?
Ian Mackenzie, MD TDP-43, FUS and new neuropathological insights

1500 hrsMichael Strong - Closing comments

Top of Page
ALS Society of Canada The ALS Association The University of Western Ontario London Health Sciences Centre ALS Society of (Windsor) Essex County
Site by ScriptReaction.com - Multi Media Development - Kevin Biskaborn - London Ontario Canada